Market Overview

'Gilead study of remdesivir in moderate #COVID19 patients out: patients on 5-day course were 65% more likely to have clinical improvement at Day 11 vs standard of care, but effect for those on 10-day course was not statistically significant' -Tweet

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for GILD

DateFirmActionFromTo
May 2020SunTrust Robinson HumphreyUpgradesSellHold
May 2020SVB LeerinkMaintainsMarket Perform
May 2020OppenheimerMaintainsOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

 

Related Articles (SPY + GILD)

Posted-In: Analyst Color News Rumors FDA Analyst Ratings Movers Media Trading Ideas

Latest Ratings

StockFirmActionPT
TYGB of A SecuritiesUpgrades
ZIONB of A SecuritiesMaintains39.0
RFB of A SecuritiesMaintains13.0
PNCB of A SecuritiesMaintains123.0
HBANB of A SecuritiesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com